Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 11, 2011, Pages 1698-1703

  Malard, Florent ^a,b   Cahu, Xavier ^a,b   Clavert, Aline ^a,b   Brissot, Eolia ^a,b   Chevallier, Patrice ^a   Guillaume, Thierry ^a   Delaunay, Jacques ^a   Ayari, Sameh ^a   Dubruille, Viviane ^a   Mahe, Beatrice ^a   Gastinne, Thomas ^a   Blin, Nicolas ^a   Harousseau, Jean Luc ^a,b   Moreau, Philippe ^a,b,c   Miplied, Noel ^a   Le Gouill, Steven ^a,b,c   Mohty, Mohamad ^a,b,c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Groupe Cytokines et Récepteurs   (France)

Author keywords

GVHD; Lymphoid malignancy; Reduced intensity conditioning

Indexed keywords

BUSULFAN; FLUDARABINE; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC GRAFT REJECTION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LOW DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 80054105565     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.04.010     Document Type: Article

References (24)

1. Thomas E., Storb R., Clift R.A., et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975, 292:832-843.
2. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110:4606-4613.
3. Champlin R., Khouri I., Komblau S., Molidrem J., Giralt S. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology (Williston Park) 1999, 13:621-628. discussion 31, 35-38, 41.
4. Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML?. Best Pract Res Clin Haematol 2007, 20:85-90.
5. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
6. Shi-Xia X, Hai-Qin X, Xian-Hua T, Bo F, Xiang-Feng T. Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta-analysis. Cell Transplant. 25:E187-E198.
7. Mengarelli A., Iori A., Guglielmi C., et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002, 87:52-58.
8. Sureda A., Robinson S., Canals C., et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008, 26:455-462.
9. Blaise D., Vey N., Faucher C., Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2007, 92:533-541.
10. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
11. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004, 32:28-35.
12. Mohty M., Jacot W., Faucher C., et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003, 17:2168-2177.
13. Brissot E., Chevallier P., Guillaume T., et al. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors. Bone Marrow Transplant 2010, 45:786-788.
14. Malard F., Szydlo R.M., Brissot E., et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:28-34.
15. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
16. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
17. Armand P., Kim H.T., Ho V.T., et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008, 14:418-425.
18. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
19. Mohty M., Labopin M., Balere M.L., et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 2010, 24:1867-1874.
20. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
21. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997, 89:3048-3054.
22. Gyurkocza B., Storb R., Storer B.E., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010, 28:2859-2867.
23. Russell J.A., Irish W., Balogh A., et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant 2010, 16:509-514.
24. Grosskreutz C., Scigliano E., Osman K., Isola L. Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin. Transplantation 2007, 84:598-604.